practical recommendations for the use of sunitinib in the treatment of metastatic kidney cancer. adverse events – potential markers of its efficacy
Clicks: 190
ID: 259488
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
4.2
/100
14 views
14 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The paper deals with the specific features of sunitinib tolerance in the treatment of metastatic renal-cell carcinoma. It considers in detail the drug’s side effects that are potential biomarkers of its efficacy.
| Reference Key |
kharkevich2014onkourologipractical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;G. Yu. Kharkevich;L. V. Demidov |
| Journal | supportive care in cancer |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.